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pressure-volume (PV) measurements to explore the relationship between diffuse myocardial ﬁbrosis and indexes
of diastolic performance in a cohort of cardiac transplant recipients.Background The precise mechanism of LV diastolic dysfunction in the presence of myocardial ﬁbrosis has not previously been
established.Methods We performed CMR with T1 mapping and obtained invasive LV PV measurements via a conductance catheter in
20 cardiac transplant recipients at the time of clinically-indicated coronary angiography.Results Both post-contrast myocardial T1 time and extracellular volume fraction correlated with b, the load-independent
passive LV stiffness constant (r ¼ 0.71, p ¼ 0.001, and r ¼ 0.58, p ¼ 0.04, respectively). After multivariate
analysis, post-contrast myocardial T1 time remained the only independent predictor of b. No signiﬁcant associations
were observed between myocardial T1 time and s, the active LV relaxation constant, or other load-dependent
parameters of diastolic function.Conclusions Diffuse myocardial ﬁbrosis, assessed by post-contrast myocardial T1 time, correlates with invasively-demonstrated
LV stiffness in cardiac transplant recipients. In patients with increased diffuse myocardial ﬁbrosis, abnormal passive
ventricular stiffness is therefore likely to be a major contributor to diastolic dysfunction. (J Am Coll Cardiol 2014;
63:1112–8) ª 2014 by the American College of Cardiology FoundationMyocardial ﬁbrosis is a fundamental event in the develop-
ment of cardiac failure (1), regardless of its etiology (2,3).
In animal models, myocardial ﬁbrosis is associated with
worsening ventricular systolic function, abnormal cardiac
remodeling, and increased ventricular stiffness (4). Myo-
cardial ﬁbrosis may be regional, as found in myocardial
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myocardial ﬁbrosis may be relevant in the pathogenesis of
heart failure with a normal left ventricular (LV) ejection
fraction, which accounts for as many as 50% of all cases of
heart failure and carries a morbidity/mortality proﬁle
comparable to that of systolic heart failure (5). Although the
detrimental effects of increasing myocardial ﬁbrosis in heart
failure still require further elucidation, a likely mechanism
is diastolic dysfunction due to increased ventricular stiffness,
which carries a poor prognosis in patients with cardiomy-
opathy in whom restrictive physiology develops (6).See page 1119Critical to our understanding of diffuse myocardial
ﬁbrosis and ventricular stiffness is the demonstration of
a mechanistic link between these 2 observed phenomena.
Using a histologically-validated cardiac magnetic resonance
(CMR) imaging post-contrast T1 mapping technique (7,8),
we previously observed in patients with advanced heart
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1113failure that increasing amounts of diffuse myocardial ﬁbrosis,
as suggested by shortened post-contrast myocardial T1 time,
are accompanied by worsening diastolic function. Subsequent
studies using a similar T1 mapping technique have observed
correlations between post-contrast myocardial T1 time and
noninvasive estimates of LV diastolic function in other disease
states, including diabetes mellitus (9,10) and hypertrophic
cardiomyopathy (11). Alternative T1 mapping approaches,
including noncontrast (native) and extracellular volume (ECV)
fraction techniques, have also been used to characterize
myocardial tissue in other conditions such as cardiac
amyloidosis (12), aortic stenosis (13), and systemic lupus ery-
thematosus (14).
Although echocardiographic index of diastolic function
have been validated against invasive LV pressure measure-
ment (15,16), these methods are sensitive to the effects of
loading conditions. Furthermore, it is virtually impossible
to noninvasively ascertain the relative contributions of active
ventricular relaxation, passive ventricular stiffness, volume
loading, and other extrinsic factors to diastolic dysfunction.
However, with the aid of accurate invasive pressure-volume
(PV) measurement, LV diastole can be broken up into
2 basic components: a decaying curve relating to active
ventricular relaxation and a passive ﬁlling pressure curve that
increases monotonically with pressure. Tau (s), the time
constant of active LV relaxation, is prolonged in diastolic
dysfunction, particularly in the presence of coexistent sys-
tolic dysfunction (17). Higher values of the passive LV
stiffness constant (b) have been demonstrated in the pres-
ence of reduced ventricular compliance, consistent with
intrinsic stiffening of the myocardium (18). In human
subjects with diastolic dysfunction, derangements of both
active relaxation and intrinsic stiffening have been impli-
cated (19).
An investigation of the relationship between diffuse
myocardial ﬁbrosis and ventricular stiffness as a putative
mechanism of diastolic dysfunction has not previously been
described. We performed CMR with post-contrast T1
mapping and obtained invasive LV PV measurements in
a cohort of cardiac transplant recipients at the time of
clinically-indicated coronary angiography to relate change
in myocardial tissue composition to intrinsic mechanical
properties of the myocardium during diastole.Methods
Patient selection. All research was performed at the
Alfred Hospital, Melbourne, Victoria, Australia. Twenty-
seven consecutive cardiac transplant recipients referred
for surveillance invasive coronary angiography were invited to
participate. Exclusion criteria included chronic atrial ﬁbril-
lation, histological evidence of allograft rejection, contrain-
dications to CMR including pacemaker and deﬁbrillator
implantation, and signiﬁcant renal dysfunction (estimated
glomerular ﬁltration rate [eGFR] <30 ml/min/1.73 m2).
Informed consent was obtained from all participants, and thestudy was conducted in accor-
dance with the Alfred Hospital
Ethics Committee’s guidelines.
Cardiac catheterization protocol.
To measure right atrial pressure,
right ventricular pressure, pul-
monary artery pressure, and pul-
monary capillary wedge pressure
(PCWP), an introducer sheath
was placed in the right femoral
vein while the patients were un-
der local anesthesia, and, under
ﬂuoroscopy, a 7-F balloon-tipped
thermodilution catheter (7-F
Arrow, Edwards Corp., Irvine,
California) was introduced. The
wedge position was conﬁrmed
ﬂuoroscopically and by the proﬁle
of the accompanying pressure waveform, and the mean
PCWP was recorded at end-expiration. Cardiac output was
measured using the thermodilution technique. Standard
invasive coronary angiography was then performed via right
femoral artery access.
A conductance catheter (CC) was used to record simulta-
neous LV PV measurements (20,21). A 7-F CC (CD Ley-
com, Zoetermeer, the Netherlands) was advanced via right
femoral artery access into the left ventricle under ﬂuoroscopic
guidance immediately after coronary angiography and con-
nected to a PV signal processor (Inca, CD Leycom). Real-
time continuous LV pressure and volume signals were
recorded for at least 30 s with patients in the supine position.
Volume calibration was performed using LV volumetric data
obtained from the same-day CMR, and CC data analysis was
performed with dedicated software (Conduct NT, CD Ley-
com). Load-dependent LV diastolic function was assessed by
left ventricular end-diastolic pressure (LVEDP), and s was
calculated using a formula previously described byWeiss et al.
(17). Load-independent LV diastolic function was evaluated
by b, using an exponential equation representing the rela-
tionship of ventricular volume to pressure during passive
ﬁlling (22): P¼ PBþAebV, where P is LV diastolic pressure,
PB is the pressure asymptote, A andb areﬁtting constants, and
V is LV diastolic volume. Curve ﬁtting to derive PB, A, and b
was performed using a graphing software package (Origin 8.5,
OriginLab Corporation, Northampton, Massachusetts).
CMR protocol. We performed CMR on all patients using
a clinical 1.5-T scanner (Signa HD 1.5-T, GE Healthcare,
Waukesha, Wisconsin) on the same day that cardiac cath-
eterization was performed. All sequences were acquired
during breath holds of 10 to 15 s. Initially, a contiguous
short-axis steady-state free precession cine stack (repetition
time ¼ 3.8 ms, echo time ¼ 1.6 ms, 30 phases) was ac-
quired, extending from the mitral valve annulus to the LV
apex (8-mm slice thickness, no gap), to enable volumetric
analysis of the left ventricle using the summation of disk
method.
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1114Late gadolinium enhancement (LGE) was evaluated
10 min after administration of a bolus of gadolinium–
diethylene triamine penta-acetic acid (0.2 mmol/kg body
weight, Magnevist, Schering, Germany) to identify regional
myocardial ﬁbrosis using a T1-weighted inversion recovery
gradient echo technique (repetition time ¼ 7.1 ms, echo
time ¼ 3.1 ms; inversion time [TI] individually determined
to null the myocardial signal; slice thickness, 8 mm; matrix,
256  192; number of acquisitions ¼ 2). To enable accurate
nulliﬁcation of healthy myocardium, a TI optimization
sequence was performed 8 min after gadolinium adminis-
tration with a fast gradient echo, inversion recovery, and
gated multiphase acquisition, commencing at an inversion
time of 150 ms and increasing in 25 ms increments to 250 ms
in a single mid-ventricular short-axis slice. LGE imaging
was performed using standard long-axis views of the left
ventricle and a contiguous short-axis stack from the mitral
valve annulus to the LV apex. Regional ﬁbrosis was identiﬁed
by LGE within the myocardium, deﬁned quantitatively by a
myocardial post-contrast signal intensity 6 SD above that
within a reference region of remote myocardium (without
LGE) within the same slice (23). LGE was deﬁned as being
present only if it was identiﬁed in 2 orthogonal views.
To evaluate diffuse myocardial ﬁbrosis, a histologically-
validated post-contrast T1 mapping sequence was used to
cycle through acquisition of images obtained at the mid-LV
short-axis level over a range of inversion times, as described
previously (7). This electrocardiogram-triggered, inversion
recovery–prepared, 2-dimensional fast gradient echo sequence
used variable temporal sampling of k-space (VAST) (24)
(Global Applied Science Laboratory, GE Healthcare). Ten
images at the mid-LV short-axis level were acquired sequen-
tially at increasing inversion times, pre-contrast (for non-
contrast myocardial T1 time; TI range, 75 to 1,875 ms) and
also 15 min after administration of the bolus of gadolinium–
diethylene triamine penta-acetic acid (TI range, 75 to 750ms),
and over a series of 3 to 5 breath holds. After image acquisition,
the 10 short-axis images of varying TIs were transferred to an
external computer for analysis using a dedicated research
software package with a curve-ﬁtting technique to generate T1
maps (Cinetool, Global Applied Science Laboratory, GE
Healthcare). For each short-axis image, a regionof interestwas
drawn around the entireLVmyocardium (excluding regions of
LGE for post-contrast images) to calculate myocardial T1
time. To account for the potential effect of glomerular ﬁltra-
tion rate on gadolinium pharmacokinetics, correction values
(25)were used to normalize post-contrastmyocardial T1 times
to a matched state (eGFR ¼ 90 ml/min/1.73 m2). Non-
contrast myocardial T1 times were corrected for heart rate
according to current recommendations (26). ECV, an alter-
nativemethodof extracellularmatrix expansionquantiﬁcation,
was derived using the previously described formula (27);
ECV¼ (1 hematocrit) (DR1myocardium/DR1blood), where
R1 ¼ 1/T1 time.
Echocardiography protocol. Transthoracic echocardiog-
raphy with a standard clinical protocol was performed onall patients immediately before cardiac catheterization.
Diastolic function was assessed by a combination of mitral
inﬂow pattern (E to A ratio) and early mitral annular ve-
locities (e0, measured at the septal and lateral aspects of the
mitral annulus in the apical 4-chamber view). Additionally,
mitral E/e0 (septal, lateral, and mean) was chosen as an index
of LV diastolic function. All measurements were made in
accordance with the American Society of Echocardiography
guidelines (28,29).
Data analysis. All echocardiographic and CMR images
were interpreted by 2 experienced readers unaware of the
subjects’ clinical information and the results of other diag-
nostic tests. Endocardial and epicardial LV contours were
drawn manually for each diastolic and systolic frame,
excluding papillary muscles. An experienced operator without
knowledge of patients’ other test results analyzed theCCdata.
Statistical analysis. All data are expressed as mean  SD
unless otherwise indicated. For all comparisons, a
p value <0.05 was considered signiﬁcant, and all reported
p values are 2-tailed. Assuming a correlation coefﬁcient
between CMR measures of diffuse ﬁbrosis (post-contrast T1
time and ECV) and invasive measures of diastolic function
(s and b) of 0.55, a sample size of 20 was required
to achieve a statistical power of 0.8, assuming a 2-tailed
p value <0.05. Correlations of variables were determined by
calculating the Pearson product moment. Multiple linear
regression was used to determine the independence of cor-
relations observed on simple linear regression. All analyses
were conducted using Stata software version 11.1 (Stata-
Corp., College Station, Texas).Results
Clinical and demographic data. Twenty of 27 patients
were included during the study period, and 7 patients were
excluded (5 due to a retained pacing or deﬁbrillator lead,
1 due to claustrophobia before CMR, and 1 due to severe
renal impairment). Baseline characteristics of the study
cohort are presented in Table 1. Most patients were male
(80%), and the mean age was 49  16 years. The median
time elapsed since cardiac transplantation was 39 months
(interquartile range: 13 to 61 months). Only 7 patients
(35%) experienced exertional dyspnea.
Cardiac catheterization data. Invasive cardiac measure-
ments obtained during right heart catheterization and cor-
onary angiography are detailed in Table 2. b was derived
from CC data for 17 patients (85%). In 1 patient, the aortic
valve could not be crossed despite multiple attempts, and
ventricular ectopy resulted in an uninterpretable PV dataset
in 2 patients. Seventeen patients had no discernible coronary
artery disease, 1 patient had an obstructive coronary artery
lesion requiring subsequent percutaneous coronary inter-
vention, and 2 patients had subtotally occluded coronary
arteries that were managed without revascularization.
CMR and echocardiography data. CMR and trans-
thoracic echocardiography were completed in all 20 patients,
Table 3
Cardiac Magnetic Resonance Imaging and
Echocardiography Data
Cardiac magnetic resonance imaging
LVEDV indexed, ml/BSA 81  20
LV stroke volume, ml 100  38
LVEF, % 62  8
LV mass indexed, g/BSA 56  12
Presence of LGE 3 (15)
Noncontrast myocardial T1 time, ms 937  158
Noncontrast blood pool T1 time, ms 1,435  335
Post-contrast myocardial T1 time, ms 380  82
Post-contrast blood pool T1 time, ms 229  34
ECV, % 26.8  8.5
Echocardiography
Left atrial volume indexed, ml/m2 59  24
Mitral E velocity, cm/s 0.8  0.2
Mitral A velocity, cm/s 0.4  0.1
E/A ratio 1.9  0.5
Deceleration time, ms 158  31
Septal e0 , cm/s 7.9  1.7
Lateral e0 , cm/s 12.4  3.7
Mean e0 , cm/s 10.1  2.1
Septal E/e0 ratio 10.7  2.4
Lateral E/e0 ratio 7.1  2.0
Mean E/e0 ratio 8.9  1.7
Values are mean  SD or n (%).
BSA ¼ body surface area; ECV ¼ extracellular volume fraction; LGE ¼ late gadolinium
enhancement; LV ¼ left ventricular; LVEDV ¼ left ventricular end-diastolic volume; LVEF ¼ left
ventricular ejection fraction.
Table 1 Baseline Characteristics
Age, yrs 49  16
Males 16 (80)
Body mass index, kg/m2 27.9  4.6





III or IV 0 (0)
Medications
Beta-blocker 3 (15)
Calcium-channel blocker 6 (30)
ACE inhibitor 8 (40)
ARB 4 (20)
Statin 18 (90)
Loop diuretic 4 (20)
Hematocrit 0.39  0.04
eGFR, ml/min/1.73 m2 66  19
Values are mean  SD, n (%), or and median (quartiles).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; eGFR ¼ estimated
glomerular ﬁltration rate; NYHA ¼ New York Heart Association.
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1115and the results are displayed in Table 3. LGE was observed
in 3 patients: 2 patients had subendocardially-based regional
scar in the vascular distribution of a subtotally occluded
coronary artery, and 1 patient had basal anteroseptal midwall
LGE of unknown etiology. Post-contrast myocardial T1
time was calculated in all 20 patients and, when corrected for
eGFR, did not different signiﬁcantly overall from uncor-
rected values (380  82 ms vs. 375  83 ms, p ¼ 0.998).
ECV could be determined in 16 patients (80%); in 4
patients, pre-contrast myocardial T1 times could not be
measured due to image artifact. ECV (26.8  8.5%) and
post-contrast T1 time showed a strong negative correlation
(r ¼ 0.82, p ¼ 0.0001) (Fig. 1).
Correlates of invasive measures of diastolic function.
Linear regression modeling revealed no signiﬁcant cor-
relations between s and patient baseline characteristics,
catheterization, CMR, or echocardiography parameters. In
particular, there was no correlation between s and non-
contrast myocardial T1 time, post-contrast myocardial T1
time, or ECV (p ¼ NS for all comparisons).Table 2 Cardiac Catheterization Data
Heart rate, beats/min 83  14
Blood pressure, mm Hg
Systolic 132  24
Diastolic 79  15
Cardiac index, l/min/m2 3.2  0.8
Right atrial pressure, mm Hg 3.6  3.2
Pulmonary artery pressure, mm Hg 15.8  4.2
Pulmonary capillary wedge pressure, mm Hg 7.5  3.2
Left ventricular end-diastolic pressure, mm Hg 14.1  8.2
Active ventricular relaxation constant (s), ms 32.6  7.4
Passive ventricular stiffness constant (b) 0.030  0.016
Values are mean  SD.Univariate linear regression demonstrated signiﬁcant
correlations between b and both post-contrast myocardial
T1 time (r ¼ 0.71, p ¼ 0.001) (Fig. 2) and ECV (r ¼ 0.58,
p ¼ 0.04) (Table 4). There were trends toward increased
PCWP and LVEDP with increasing b (r ¼ 0.47, p ¼ 0.06,
and r ¼ 0.39, p ¼ 0.12, respectively). No correlation
was observed between b and noncontrast myocardial T1Figure 1
Post-Contrast Myocardial T1 Time and
Extracellular Volume Fraction
A signiﬁcant negative correlation was observed between post-contrast T1 time
and extracellular volume fraction (r ¼ 0.82, p ¼ 0.001).
Figure 2
Post-Contrast Myocardial T1 Time and
Passive Left Ventricular Stiffness Constant
A signiﬁcant positive negative correlation was observed between post-contrast
myocardial T1 time and passive left ventricular stiffness constant, b (r ¼ 0.71,
p ¼ 0.001).
Ellims et al. JACC Vol. 63, No. 11, 2014
T1 Mapping and Left Ventricular Stiffness March 25, 2014:1112–8
1116time or with CMR-derived LV volumetric parameters or
echo-cardiographically-determined measures of LV diastolic
function. Given the strong correlation between post-contrast
myocardial T1 time and ECV, these variables were entered






Body mass index 0.23
NYHA functional class 0.07
Time since transplantation 0.29
Cardiac catheterization parameters
Heart rate 0.16
Systolic blood pressure 0.22




Cardiac magnetic resonance imaging parameters
LVEDV indexed 0.25
LVEF 0.02
LV mass indexed 0.16
Noncontrast myocardial T1 time 0.25
Post-contrast myocardial T1 time 0.71
ECV 0.58
Echocardiography parameters
Left atrial volume indexed 0.21
Mean E/e0 ratio 0.02
LVEDP ¼ left ventricular end-diastolic pressure; PCWP ¼ pulmonary capillar
in Tables 1 and 3.analysis, only the correlation between b and post-contrast
myocardial T1 time remained signiﬁcant.Discussion
To our knowledge, this is the ﬁrst study to demonstrate a
physiological link between diffuse myocardial ﬁbrosis
assessed by post-contrast myocardial T1 time, and an
invasively-determined index of LV diastolic stiffness. Myocar-
dial T1 time, obtained at a single time point after contrast
administration, and ECV, calculated from pre- and post-
contrast myocardial and blood pool signals, both correlated
with b, the load-independent LV passive stiffness constant.
Post-contrast myocardial T1 times have previously been
shown to correlate with the quantity of diffuse myocardial
ﬁbrosis observed in endomyocardial biopsy specimens (7,8),
and several T1 mapping studies have observed associations
between reduced T1 times and LV diastolic dysfunction as
assessed by echocardiography (9–11). However, because
echocardiographic studies use integrated backscatter and
Doppler techniques that reﬂect both structural and func-
tional changes in the myocardium, the precise mechanism
of diastolic impairment has not been established. Compared
with echocardiography, T1 mapping by CMR is a tissue-
speciﬁc modality that allows the unique opportunity to
directly assess the structural components of the myocardium










p Value b p Value b p Value
0.4 0.11 0.7 0.50 0.15
0.4 0.15 0.5 0.18 0.5
0.8
0.3 0.29 0.18 0.32 0.3
0.5 0.08 0.8 0.24 0.4
0.4 0.28 0.4 0.37 0.5
0.7
0.4
0.06 0.07 0.8 0.39 0.4
0.12 0.29 0.3 0.04 0.9
0.3
0.9
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1117study, by performing invasive PV measurements, active
relaxation, an energy-dependent process, and passive ﬁlling
could be evaluated independently and then correlated with
T1 time.
In patients with LV systolic dysfunction and heart failure
with a normal ejection fraction, myocardial ﬁbrosis is
believed to contribute to increased passive LV stiffness (30).
Given the diffuse nature of collagen deposition in cardio-
myopathy, a noninvasive test for myocardial ﬁbrosis is highly
desirable, not just in terms of disease stratiﬁcation, but also
in the evaluation of newer therapies aimed at minimizing
or reducing myocardial ﬁbrosis in the treatment of heart
failure. For example, therapies inhibiting the angiotensin II
system may have antiﬁbrotic properties (31,32), and T1
mapping could theoretically be used to noninvasively
monitor the amount of diffuse myocardial ﬁbrosis present,
allowing longitudinal assessment of the potential impact of
such treatments on ventricular stiffness.
We observed correlations between post-contrast myocar-
dial T1 times and b, but not load-dependent measures of
LV diastolic function such as LVEDP and the ratio of early
mitral transmitral velocity to tissue Doppler mitral annular
early diastolic velocity (E/e0, by echocardiography). In
addition, active LV relaxation (s) did not correlate with
CMR indexes of diffuse myocardial ﬁbrosis, suggesting that
it is the intrinsic properties of the myocardium due to diffuse
ﬁbrosis and hence increased stiffness rather than perturbation
of the energy-dependent active relaxation process that un-
derlines the mechanism of diastolic dysfunction commonly
observed in our patient cohort (33).
We found that although post-contrast myocardial T1 time
and ECV correlated with b, only the relationship between
the post-contrast myocardial T1 time and b remained sta-
tistically signiﬁcant after multiple linear regression analyses.
Noncontrast myocardial T1 time exhibited no signiﬁcant
correlation with b. Post-contrast T1 mapping times have
been shown to correlate with the quantity of diffuse inter-
stitial ﬁbrosis seen on myocardial biopsy specimens (8),
whereas noncontrast T1 measurements, which are used to
calculate ECV and native T1 times, reﬂect a combination of
both interstitial and myocardial signals. Therefore, precisely
which altered tissue characteristics contribute to noncontrast
values are uncertain. Various T1 mapping approaches
currently exist and are likely to provide different information
about myocardial tissue characteristics. Nevertheless, our
data identify a clear relationship between post-contrast
myocardial T1 time and LV passive stiffness. It is possible
that other T1 mapping protocols may demonstrate differing
degrees of correlation with b, and future studies will be
required to investigate this further.
Cardiac transplant recipients were chosen to form the
study cohort because they provided opportunities to obtain
invasive PV measurements at the time of clinically-indicated
coronary angiography. Additionally, diffuse myocardial
ﬁbrosis has been shown to occur in w50% of cardiac
transplant recipients (34), and the likelihood of pre-existing,and potentially confounding, cardiac conditions, such as
hypertensive LV hypertrophy, signiﬁcant valvular heart
disease, and cardiomyopathy, was low. However, the
generalizability of our ﬁndings to other cardiac disease states
will need to be conﬁrmed with further studies. For instance,
in patients with ischemic cardiomyopathy, impairment
of the energy-dependent process of active relaxation may
also contribute to diastolic dysfunction without necessarily
affecting T1 time.
Study limitations. Because only a limited number of car-
diac transplantations are performed, and a signiﬁcant pro-
portion of potentially eligible patients have contraindications
to CMR, our overall study cohort size is small. Additionally,
all recruited patients had either absent or mild symptoms
of LV diastolic dysfunction, and overall intracardiac pres-
sures were normal. Repeating our protocol in patients with
more pronounced heart failure symptoms and higher intra-
cardiac pressures would be of interest. The effect of various
physiological maneuvers, such as exercise, on invasively-
determined diastolic indexes was also not investigated in this
study and may represent a focus for future research.
Conclusions
Diffuse myocardial ﬁbrosis, assessed by post-contrast myo-
cardial T1 time, correlates with invasively-determined LV
stiffness in cardiac transplant recipients. In patients with
increased diffuse myocardial ﬁbrosis, abnormal passive ven-
tricular stiffness is therefore likely to be a major contributor
to diastolic dysfunction. The ability to noninvasively evaluate
ventricular stiffness using T1 mapping in a variety of car-
diomyopathies may enhance our understanding of the
pathogenesis and natural history of these conditions and
enable the therapeutic trials of putative antiﬁbrotic agents.
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